Clinical Trials - June 9, 2015
Good News for Novo Drug
New phase 3b findings showed adults with type 2 diabetes treated with Novo Nordisk’s Xultopha, demonstrated statistically significant reduction in HbA1c, change in body weight and a lower rate of hypoglycemia compared with patients treated with insulin glargine. Findings from the phase 3b DUAL(TM) V 26-week trial that compared the efficacy and safety of Xultophy® […]
Drug Development Pharma - June 9, 2015
Janssen Submits BLA to FDA
Genmab A/S’s licensing partner Janssen Biotech, Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for daratumumab for double refractory multiple myeloma. The submission is for using daratumumab to treat patients with multiple myeloma who have received at least three different lines of therapy […]
Clinical Trials - June 8, 2015
ALK Partner Testing Allergy Drug
ALK’s partner MSD has produced encouraging results from a North American Phase III clinical trial of ALK’s investigational sublingual allergy immunotherapy tablet for the treatment of house dust mite allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favor of HDM SLIT-tablet compared with placebo, according to BioSpace.com. The primary endpoint […]
Clinical Trials - June 8, 2015
Novo Drug Works During Ramadan Fast
Adults with type 2 diabetes treated with Novo Nordisk’s Victoza®, in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus metformin, according to a recent study. People treated with Victoza® also demonstrated greater weight loss and fewer confirmed hypoglycemic episodes compared with […]
New Market - June 8, 2015
AZ’s Interest in Immuno-oncology Grows
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the body’s own immune system to attack cancer cells, according to BioSpace.com. The companies reported on a number of pipeline […]
Pharma Diagnostics - June 6, 2015
Celiac Disease Underdiagnosed
Rsearch recently released by the University of Copenhagen shows that celiac disease (CD) is signicantly under-diagnosed in adults and can lead to major health complications. The study, published in the Scandinavian Journal of Gastroenterology, supports previous research indicating that symptom-based diagnosis alone may be inadequate. The Danish researchers performed serological testing on adults from the […]
